AN6.F AnaptysBio Inc.

Healthcare Biotechnology Frankfurt Exchange
42.74 EUR
Close of Nov 11, 2026
28.40 61.48
Market cap
EUR 1.28B
P/E
-
P/B
133.77x
ROE
-1,659.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.

Is AN6.F undervalued?

Graham number

The Graham number of AnaptysBio Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AnaptysBio Inc. fundamental analysis

No fundamental analysis for AnaptysBio Inc. yet.

AnaptysBio Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AnaptysBio Inc.

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agr…

Full company profile